- Case-Based Modules
- Initial Evaluation
- Dermatologic Manifestations
- Oral Manifestations
- OIs: Prophylaxis
- OIs: Treatment
- Antiretroviral Rx
- Antiretroviral Rx: Resistance
- Antiretroviral Rx: Adverse Effects
- Drug-Drug Interactions
- Postexposure Prophylaxis
- Perinatal Transmission
- Special Populations
- Prevention for Positives
- Challenging Unknowns
- Resource-Limited Settings
- Interactive Tutorials
- Routine HIV Screening
- Oraquick Advance Rapid HIV Test
- HIV Integration
- This program is funded through Health Resources and Services Administration, US Department of Health and Human Services.
Opportunistic Infections: Treatment
Question | Discussion | References | CME Credit
Case 4: A 32-Year-Old with Fever, Weight Loss, and Fatigue
You answered:
 |
The 2002 U.S. Public Health Service 2002 Guidelines for Preventing Opportunistic Infections state that secondary prophylaxis (to prevent recurrence of disseminated MAC) may be discontinued in patients treated with HAART who have a sustained (greater than 6 months) increase in CD4 count to greater than 100 cells/mm3 if they have completed 12 months of MAC therapy and have no ongoing symptoms or signs attributable to MAC. |
|---|
This answer is correct. Several studies have shown that patients who have been treated for disseminated MAC and have a sustained response to HAART are unlikely to develop recurrent disseminated MAC if they discontinue maintenance therapy for MAC. These studies led to the recommendation in the 2002 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections that secondary prophylaxis for MAC may be discontinued in patients treated with HAART who have a sustained (greater than 6 months) increase in CD4 count to greater than 100 cells/mm3 if they have completed 12 months of MAC therapy and have no ongoing symptoms or signs attributable to MAC.
[Back to Case 4 Question | Proceed to Case 4 Discussion]
Copyright © 2004-2013 University of Washington